Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

This article was originally published here

Ther Adv Musculoskelet Dis. 2021 Jul 9;13:1759720X211025894. doi: 10.1177/1759720X211025894. eCollection 2021.


Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of such treatment has to take into account the patient’s comorbidities. Neurologic diseases are common and their association with SpA deserves to be studied. Therefore, the role of TNF-α and IL-17 cytokines is worth investigating in these neuropsychiatric diseases. This review aimed to explore the role of TNF-α and IL-17 in the pathogenesis of uveitis, multiple sclerosis, neuromyelitis optica, Alzheimer’s disease, Parkinson’s disease and depression. This update is critical to guide the therapeutic management of these co-morbidities in SpA patients.

PMID:34290832 | PMC:PMC8273400 | DOI:10.1177/1759720X211025894